稳定期系统性红斑狼疮患者发作的预测因素
该研究纳入210例东南亚SLE患者(70.5%为华人),中位随访31.5个月,72.4%基线为稳定期,51.9%出现发作。稳定期患者中,最低年龄三分位、血小板减少、低补体血症及最高基线泼尼松龙剂量与发作风险升高相关,而最短病程三分位与发作风险降低相关。
要点
- 稳定期SLE患者发作常见,中位随访31.5个月后51.9%发作。
- 最低年龄三分位、血小板减少、低补体血症、最高基线泼尼松龙剂量预测发作。
- 最短病程三分位与发作风险降低相关。
核心结论
- 在亚洲初始稳定期SLE患者中发作常见,需对年轻、长病程、血小板减少、低补体血症或基线泼尼松龙剂量较高者密切监测。
研究设计与样本
- 连续纳入符合1997年ACR或2012年SLICC标准的成人SLE患者,每3个月随访,采用SELENA-SLEDAI发作指数定义发作,用Cox比例风险模型分析稳定期(SLEDAI-2K≤4)患者的基线预测因素。
主要发现
- 210例患者中148例(70.5%)为华人,基线中位SLEDAI-2K为2(IQR 0-4),中位病程10年(IQR 4.4-16.4)。
- 152例(72.4%)基线为稳定期,中位随访31.5个月(IQR 24.1-36.3)后109例(51.9%)发作。
- 稳定期发作患者中,最低年龄三分位HR 3.08(95%CI 1.72-5.48,p<0.01),血小板减少HR 5.01(95%CI 1.32-18.99,p=0.02),低补体血症HR 3.35(95%CI 1.54-7.30,p<0.01),最高基线泼尼松龙剂量HR 2.39(95%CI 1.28-4.46,p=0.01)。
- 最短病程三分位与发作风险降低相关,HR 0.41(95%CI 0.21-0.80,p=0.01)。
临床怎么用
- 对稳定期SLE患者,应评估年龄、病程、血小板计数、补体水平及基线泼尼松龙剂量以识别发作高风险者。
- 对年轻、长病程、血小板减少、低补体血症或基线泼尼松龙剂量较高的稳定期患者加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data on flares in Asian patients with systemic lupus erythematosus (SLE) are scarce. Here, we aim to identify the baseline predictors of flares in a cohort of Southeast Asian patients with SLE. METHODS: Consecutive adult patients with prevalent SLE according to the 1997 ACR or 2012 SLICC criteria were enrolled and followed three-monthly. Clinical and laboratory data were collected at every visit using a standardised protocol. Flares were defined using the SELENA-SLEDAI Flare Index (SFI). Baseline predictors of flare in patients with stable disease (SLE Disease Activity Index-2K (SLEDAI-2K) of ≤ 4) were determined using Cox proportional hazards. RESULTS: Of the 210 patients recruited, 148 (70.5%) were Chinese. The median (IQR) SLEDAI-2K at entry was 2 (0-4) and the median (IQR) disease duration was 10 (4.4-16.4) years. At baseline, 152 (72.4%) patients had stable disease. After a median (IQR) follow-up of 31.5 (24.1-36.3) months, 109 (51.9%) flared. Stable patients who flared tended to be in the lowest tertile of age (HR 3.08, 95% CI 1.72-5.48, p < 0.01), had thrombocytopenia (HR 5.01, 95% CI 1.32-18.99, p = 0.02), hypocomplementemia (HR 3.35, 95% CI 1.54-7.30, p < 0.01) and had the highest baseline prednisolone doses (HR 2.39, 95% CI 1.28-4.46, p = 0.01). Conversely, patients in the lowest tertile of disease duration tended not to flare (HR 0.41, 95% CI 0.21-0.80, p = 0.01). CONCLUSION: Flares are common in Asian SLE patients with initial stable disease. Close monitoring is needed for patients who are younger, with longer disease duration, thrombocytopenia, hypocomplementemia, or who required a higher baseline prednisolone dose.
引用
- Cho J, Lahiri M, Teoh LK, et al. Predicting flares in patients with stable systemic lupus erythematosus. Semin Arthritis Rheum. 2019. PMID: 30660381. doi:10.1016/j.semarthrit.2019.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。